jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Anti-ro SSA-IgG Antibodies by EIA

Immunity
image

Report in 96Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Anti-Ro (SSA) antibodies are autoantibodies directed against Ro ribonucleoproteins, which are involved in RNA processing. Their presence is associated with various systemic autoimmune diseases.

₹2,100₹2,870

27% OFF

Anti-Ro SSA-IgG Antibodies by EIA - Comprehensive Medical Test Guide

  • Section 1: Why is it done?
    • Test Purpose: Detects IgG antibodies against Ro52 and Ro60 antigens using Enzyme Immunoassay (EIA). These autoantibodies are associated with autoimmune diseases, particularly Sjögren's syndrome and systemic lupus erythematosus (SLE).
    • Primary Indications for Testing: Suspected Sjögren's syndrome with dry mouth and dry eyes, suspected or confirmed SLE diagnosis, family history of autoimmune diseases, recurrent photosensitive rashes, recurrent oral ulcers, unexplained salivary gland enlargement, investigation of abnormal ANA results.
    • Special Circumstances for Testing: Pregnant women with Ro/SSA antibodies (neonatal lupus risk assessment), patients with unexplained cardiac conduction abnormalities, initial diagnosis confirmation of connective tissue disease, disease monitoring and progression assessment.
  • Section 2: Normal Range
    • Reference Range Values: < 1.0 U/mL (or < 1.0 Index) = Negative/Normal 1.0 - 1.2 U/mL (or 1.0 - 1.2 Index) = Borderline/Equivocal > 1.2 U/mL (or > 1.2 Index) = Positive/Abnormal Note: Reference ranges may vary by laboratory methodology and equipment used.
    • Units of Measurement: U/mL (Units per milliliter) or Index units, with some laboratories reporting as numerical ratios or optical density values.
    • Result Interpretation Guide: Negative: No detectable anti-Ro SSA IgG antibodies present; typically seen in healthy individuals without autoimmune disease. Borderline: Results in uncertain zone; may require repeat testing or clinical correlation with symptoms; some laboratories recommend retesting within 4-6 weeks. Positive: Antibodies detected; indicates current or past immune response to Ro SSA antigens; clinically significant and warrants further evaluation and specialist referral.
  • Section 3: Interpretation
    • Negative Result Interpretation: Suggests absence of anti-Ro SSA autoimmunity; however, does not completely exclude Sjögren's syndrome or SLE as other antibodies (Anti-La, ANA) may be present. Particularly reassuring in pregnant women regarding neonatal lupus risk.
    • Mildly to Moderately Positive (1.2 - 5.0 U/mL): Consistent with Sjögren's syndrome or seronegative SLE; correlate with clinical symptoms; recommend rheumatology referral for further assessment and additional serologic testing.
    • Highly Positive (> 5.0 U/mL): Strong evidence of autoimmune disease, particularly Sjögren's syndrome; associated with significant clinical manifestations; requires prompt evaluation and specialist consultation; increased risk of systemic complications.
    • Factors Affecting Test Results: Timing of antibody development (may take weeks after symptom onset), disease activity level, concurrent immunosuppressive therapy (may reduce antibody levels), presence of immunoglobulin abnormalities, technical variations in EIA methodology between laboratories, sample handling and storage conditions.
    • Clinical Significance Patterns: Anti-Ro SSA positive with Anti-La negative: May indicate seronegative SLE or variant Sjögren's syndrome. Anti-Ro SSA and Anti-La both positive: Highly specific for primary Sjögren's syndrome. Anti-Ro SSA positive with positive ANA: Strongly suggestive of SLE or SLE-related condition. Positive in pregnancy: Requires fetal monitoring for neonatal lupus and cardiac complications.
  • Section 4: Associated Organs
    • Primary Organ Systems Involved: Exocrine glands (salivary and lacrimal), immune system (B and T lymphocytes), connective tissue throughout body.
    • Primary Diseases Associated with Positive Results: Primary Sjögren's syndrome (SSA-positive in 40-60% of cases), Secondary Sjögren's syndrome (associated with SLE, rheumatoid arthritis, other connective tissue diseases), Systemic lupus erythematosus (SLE) and SLE variants, Neonatal lupus (in infants born to positive mothers), Lupus-related photosensitivity dermatitis.
    • Secondary Conditions and Complications: Congenital heart block (in neonates), Recurrent infections (secondary to glandular dysfunction), Systemic inflammation affecting kidneys (glomerulonephritis), Vasculitis and vessel inflammation, Thyroid disorders and autoimmune thyroiditis, Peripheral neuropathy, Pulmonary fibrosis, Lymphoid malignancy (increased risk).
    • Potential Organ System Complications: Renal system: membranoproliferative glomerulonephritis, chronic kidney disease. Cardiac: conduction abnormalities, pericarditis. Pulmonary: interstitial lung disease, pulmonary fibrosis. Hematologic: cytopenias, lymphoproliferative disorders. Neurologic: cognitive dysfunction, peripheral neuropathy. Rheumatologic: arthritis, myositis.
  • Section 5: Follow-up Tests
    • Recommended Initial Follow-up Testing (if Positive): Anti-La (SSB) IgG antibodies - frequently positive alongside Anti-Ro in Sjögren's syndrome; more specific indicator. Antinuclear antibody (ANA) panel - assess for additional autoimmune markers. Anti-centromere, anti-histone, anti-dsDNA antibodies - evaluate SLE subtype. Rheumatoid factor (RF) - assess rheumatoid disease involvement.
    • Complementary Systemic Assessment Tests: Complete blood count (CBC) - screen for cytopenias. Comprehensive metabolic panel (CMP) - assess kidney and liver function. Urinalysis - evaluate for proteinuria and hematuria. Erythrocyte sedimentation rate (ESR) - measure inflammation. C-reactive protein (CRP) - additional inflammation marker.
    • Organ-Specific Follow-up Tests: Renal evaluation: 24-hour urine protein, serum creatinine, glomerular filtration rate (GFR). Pulmonary: chest X-ray, high-resolution CT chest, pulmonary function tests. Cardiac: EKG (specifically evaluate for conduction abnormalities), echocardiography if clinically indicated, Holter monitor if conduction defects suspected. Ophthalmic: Schirmer test, tear osmolarity (for Sjögren's diagnosis). Oral: unstimulated salivary flow rate, sialography if indicated.
    • Specialized Tests for Specific Populations: Pregnant women: fetal echocardiography, serologic testing in each trimester. Neonates of positive mothers: ECG (congenital heart block screening), echocardiography, anti-Ro SSA testing at birth and 6 months.
    • Monitoring Frequency and Schedule: Repeat Anti-Ro SSA testing: Typically not repeated unless clinical status changes significantly or diagnosis being reconsidered. Initial diagnosis workup: Complete within 4-8 weeks of positive result. Annual monitoring: CBC, CMP, urinalysis if diagnosed with Sjögren's or SLE. More frequent monitoring (quarterly to semi-annually): If active disease, immunosuppressive therapy initiated, or complications developing.
    • Rheumatology Specialist Consultation Triggers: Any positive result warrants rheumatology evaluation. Urgent referral (within 2 weeks) if: pregnancy, cardiac symptoms, renal involvement, pulmonary symptoms, cytopenias, or neurologic manifestations present.
  • Section 6: Fasting Required?
    • Fasting Requirement: NO - Fasting is NOT required for Anti-Ro SSA-IgG antibody testing. This test can be performed on a non-fasting blood sample.
    • Patient Preparation Instructions: Standard blood collection: Patient may eat and drink normally before test. No dietary restrictions necessary. Patient should be well-hydrated for easier venipuncture. Wear comfortable, loose-fitting upper clothing for blood draw access.
    • Medications and Supplements: Continue all regular medications unless otherwise instructed by healthcare provider. Immunosuppressive medications should NOT be stopped prior to testing; inform laboratory of current immunosuppressive therapy. Herbal supplements: Generally no restrictions; may continue as normal. Corticosteroids: Continue as prescribed; may reduce antibody levels but does not invalidate test results.
    • Additional Special Preparation Requirements: Timing considerations: Test can be performed any time of day; no time-dependent restrictions. Active infection: May perform test during active infection; antibodies may be temporarily elevated. Stress or illness: No significant impact on test results; test can proceed during acute stress or minor illness. Recent vaccinations: No specific restrictions; inform healthcare provider of recent immunizations (usually no impact on antibody testing).
    • Sample Collection Specifications: Collection method: Standard venipuncture. Volume required: Typically 5-7 mL of serum. Tube type: Serum separator tube (SST) or plain red-top tube. Handling: Keep at room temperature initially; separate serum within 1-2 hours of collection. Transport: Room temperature or refrigerated depending on laboratory protocol. Stability: Serum stable at room temperature for several hours; refrigerated for up to 1 week; can be frozen for longer storage.
    • Pre-Test Communication with Healthcare Provider: Inform provider if: Recently diagnosed with infection or undergoing antibiotic therapy, currently pregnant or planning pregnancy, receiving biologic or immunosuppressive therapy, have active systemic symptoms, prior abnormal antibody results, family history of autoimmune disease.

How our test process works!

customers
customers